ArticleMolecular psychiatry2018
A novel 5HT3 receptor-IGF1 mechanism distinct from SSRI-induced antidepressant effects.
Article in Molecular psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 38 citations in OpenAlex.
- Low-Dose Digoxin Ameliorates Age-Related Motor Learning Deficits in Mice.Neurochemical research · 2026Article
- The Complex Role of Serotonin-Dopamine-Glutamate Receptors in Major Depression.Advances in experimental medicine and biology · 2026Review
- Prenatal green space exposure and child's cognition: mediation by cord blood IGF1 in the ENVIRONAGE birth cohort.Environment international · 2025Article
- Central Insulin-like Growth Factor-1 Treatment Enhances Working and Reference Memory by Reducing Neuroinflammation and Amyloid Beta Deposition in a Rat Model of Sporadic Alzheimer's Disease.Pharmaceuticals (Basel, Switzerland) · 2025Article
- The interface of depression and diabetes: treatment considerations.Translational psychiatry · 2025Review
- N-(3-((3-(trifluoromethyl)phenyl)selanyl)prop-2-yn-1-yl) benzamide induces antidepressant-like effect in mice: involvement of the serotonergic system.Psychopharmacology · 2024Article
- In Vivo Brain Microdialysis.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Serotonergic mediation of the brain-wide neurogenesis: Region-dependent and receptor-type specific roles on neurogenic cellular transformation.Current research in neurobiology · 2023Review
- Adult enteric Dclk1-positive glial and neuronal cells reveal distinct responses to acute intestinal injury.American journal of physiology. Gastrointestinal and liver physiology · 2022Article
- IGF-1 release in the medial prefrontal cortex mediates the rapid and sustained antidepressant-like actions of ketamine.Translational psychiatry · 2022Article
- Insulin-like growth factor I mitigates post-traumatic stress by inhibiting AMP-kinase in orexin neurons.Molecular psychiatry · 2022Article
- Antidepressant-like effects of trophic factor receptor signaling.Frontiers in molecular neuroscience · 2022Review
- Relationship between hepatocellular carcinoma and depression via online database analysis.Bioengineered · 2021Article
- Association between the serum insulin-like growth factor-1 concentration in the first trimester of pregnancy and postpartum depression.Psychiatry and clinical neurosciences · 2021Article
- Constitutive Activity of Serotonin Receptor 6 Regulates Human Cerebral Organoids Formation and Depression-like Behaviors.Stem cell reports · 2021Article
- Jie-Yu-He-Huan Capsule Ameliorates Anxiety-Like Behaviours in Rats Exposed to Chronic Restraint Stress via the cAMP/PKA/CREB/BDNF Signalling Pathway.Oxidative medicine and cellular longevity · 2021Article
- Bladder urothelium converts bacterial lipopolysaccharide information into neural signaling via an ATP-mediated pathway to enhance the micturition reflex for rapid defense.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression is a common mental disorder affecting around 350 million people worldwide. Although selective serotonin reuptake inhibitors (SSRIs) are the most widely used antidepressants, a significant proportion of depressed patients do not achieve remission with SSRIs. In this study, we show that a serotonin type 3 receptor (5HT3R) agonist induces antidepressant effects as well as hippocampal neurogenesis independent of fluoxetine (a commonly used SSRI). Notably, our histological analysis reveals that 5HT3R and insulin-like growth factor 1 (IGF1) are expressed in the same neurons in the subgranular zone of the hippocampal dentate gyrus. Furthermore, our in vivo microdialysis analysis shows that 5HT3R regulates hippocampal extracellular IGF1 levels, and we also show that 5HT3R-dependent hippocampal neurogenesis is mediated by increased IGF1 levels. Altogether, our findings suggest a novel 5HT3R-IGF1 mechanism that is distinct from fluoxetine-induced responses and that provides a new therapeutic target for depression, especially bringing significant benefits for SSRI-resistant depressed patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.